Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 97 full-time employees. The company went IPO on 2021-03-11. The firm discovers, develops and commercializes therapeutic products for the treatment of immune-mediated diseases, inflammatory bowel disease. Its precision medicine platform, Prometheus360, includes gastrointestinal bioinformatics databases and sample biobanks, to identify therapeutic targets, develop therapeutic candidates to engage those targets, and develop genetics-based diagnostic tests designed to identify patients to respond to its therapeutic candidates. Its lead product candidate, PRA023, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block the tumor necrosis factor (TNF). Its second product candidate, PRA052, is an anti-CD30L mAb. The CD30L-CD30 co-stimulatory pathway has been implicated in IBD by genetic, preclinical and human translational data. Its PR1100 program targets the receptor for a pro-inflammatory cytokine that has been linked to multiple immune-mediated diseases.

Industry: Pharmaceutical Preparations Peers: BioCryst Pharmaceuticals Inc EQRx, Inc. Fate Therapeutics Inc Insmed Inc Relay Therapeutics Inc Sage Therapeutics, Inc. Prokidney Corp Twist Bioscience Corp Vir Biotechnology Inc